Eli Lilly (LLY) has seen its shares soar 400% over the past five years, driven by the explosive growth of its GLP-1 weight loss drugs. In contrast, Novo Nordisk (NVO) has only gained 20% and is down 60% from its recent peak, while Pfizer (PFE) has dropped 33%. Despite Eli Lilly’s robust business performance, its high price-to-earnings ratio of 34x—well above the industry average of 23x—indicates that the stock may be overvalued, prompting investors to consider alternatives.
Novo Nordisk recently launched a GLP-1 pill that is outperforming Eli Lilly’s offerings, leading to a revised full-year guidance and a 4% dividend yield, making it an attractive option for conservative investors. Pfizer, while currently sidelined in the GLP-1 race, is pivoting with new acquisitions and has a strong dividend yield of 6.5%, despite its challenges.
For market professionals, the key takeaway is to evaluate the potential upside in Novo Nordisk and Pfizer, both of which may offer more attractive valuations compared to the richly priced Eli Lilly.
Source: fool.com